New Health Sciences


HVA Platform

NHSi delivers HVA via a proprietary internet-based software platform – the HVA Platform.

HVA measures, refines and analyses raw data from traditional TCD from up to 23 vessel segments to establish a hemodynamic pattern unique to each individual tested. It combines three widely accepted physiological measures (see figure 1 below) per vessel into an integrated neurovascular profile or “score” that is precise, clinically significant and easily interpretable.

Existing TCD equipment is used to scan patients at the point of care; gathering and extracting blood flow data from ultrasound signals for each of the 23 intracranial vessels (see Figure 2).

HVA

The data is then transmitted via Internet connection to NHSi servers, where proprietary analytical software is used to calculate the three standard TCD measures. The platform automatically compiles the patient’s data and compares it to the Company’s proprietary reference database of asymptomatic subjects (see Figure 3).

In near real time the HVA platform delivers via the Internet a comprehensive report describing the patient’s hemodynamic state. This report shows TCD parameters as standard deviations from reference values in both visual and numeric form and, where needed, also integrates additional hemodynamic or clinical information (see Figure 4).

“NHSi’s HVA platform promises to enhance greatly the relevance and utility of TCD and other hemodynamic data in the diagnosis and management of neurovascular disease, and in the development and assessment of therapies for those diseases. I look forward to continuing my work with NHSi’s leadership to realize its full scientific and commercial potential.
Rune Aaslid, Ph.D.
(Department of Neurosurgery, Uni. of Bern, Switzerland)
Inventor of TCD, author of seminal publications in neurovascular hemodynamics.

Included in the HVA report, as shown in the example to the below looking at profiles for dementia, is a graphical representation of the statistical relationship of each of the 23 intracranial vessels to the asymptomatic norm derived from the database along three standard TCD measurements. Together they form a highly recognizable “profile” of normal and disease conditions.

The first Panel shows a composite HVA profile of all 71-80 year old members of the asymptomatic database as compared to the mean of the entire asymptomatic database for each of the three TCD parameters for each of the 23 measured vessels. The next Panel shows the same information for a single patient diagnosed with dementia. The last Panel shows the same patient one year later evidencing a more pronounced dementia profile.

This ability to compare symptomatic patients against an asymptomatic reference norm and to track disease progression and response to therapy is an important new tool for clinicians. The profiles generated by HVA enable more accurate diagnoses and management of therapies, resulting in reduced costs and improved patient outcomes.

HVA HVA HVA

Contact Us

New Health Sciences, Inc.
6903 Rockledge Drive, Suite 230
Bethesda, MD 20817-1818
Map

(301) 493-5550 (telephone)
(301) 493-4360 (fax)

Contact Us